Actively Recruiting
Assessment of Clonal Hematopoiesis and Its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors
Led by Children's Oncology Group · Updated on 2026-05-05
190
Participants Needed
32
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to understand how blood cell growth patterns called therapy-related clonal hematopoiesis t-CH are linked to heart health or cardiovascular disease in patients who were treated for classical Hodgkin lymphoma during childhood or adolescence. It focuses on patients who received anthracycline chemotherapy and explores how these blood cell changes might predict future heart problems. The study is observational and seeks to identify patients at higher risk so they can be monitored more closely for early detection and prevention of heart complications. Participants undergo several procedures including blood sample collection, surveys, and cardiac magnetic resonance imaging MRI. Their medical records are also reviewed, and archived blood samples may be collected if available. The study compares the presence of t-CH mutations in patients with and without signs of cardiovascular disease and evaluates various factors like radiation exposure, age, sex, and medication use to understand their impact on t-CH and heart health. During the study, participants provide blood samples and complete surveys while undergoing cardiac MRI without sedation. Researchers analyze these data along with medical records to assess blood cell mutations and heart function. The main outcome measured is the presence of therapy-related clonal hematopoiesis linked to cardiovascular disease within one year. Secondary evaluations look at changes over time and associations with clinical risk factors. The study helps monitor heart health risks after lymphoma treatment and runs until 2028.
CONDITIONS
Brief Title
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient must be 63; 7 years of age at the time of enrollment (age to perform an MRI without sedation).
- History of pathologically confirmed classical Hodgkin Lymphoma initially diagnosed between ages 63; 2 and < 22 years.
- Received a cumulative doxorubicin equivalent anthracycline dose of 63; 200 mg/m�b2 as part of frontline therapy.
- All systemic cancer treatment completed 63; 2 years prior to study enrollment.
- Not known to have had relapse, second malignancy, or death.
- Access to cardiac MRI at the enrolling institution and able to complete MRI without sedation.
You will not qualify if you...
- Medical contraindication to non-contrast cardiac MRI.
- Diagnosis of nodular lymphocyte-predominant Hodgkin Lymphoma.
- Received cancer therapy beyond initial Hodgkin Disease treatment.
- History of CTCAE grade 3 or higher cardiovascular disease existing before Hodgkin Lymphoma diagnosis, except resolved congenital conditions or managed chronic conditions.
- History of immunodeficiency prior to Hodgkin Lymphoma diagnosis, including primary immunodeficiency syndromes, organ transplant recipients, or systemic immunosuppressive therapy.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here